Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal antibody, represents a mainstay in the treatment of HER2-positive (HER2(+)) breast cancer. Although trastuzumab treatment is highly efficacious for early-stage HER2(+) breast cancer, the majority of advanced-stag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Upton, Rosalynd, Banuelos, Allison, Feng, Dongdong, Biswas, Tanuka, Kao, Kevin, McKenna, Kelly, Willingham, Stephen, Ho, Po Yi, Rosental, Benyamin, Tal, Michal Caspi, Raveh, Tal, Volkmer, Jens-Peter, Pegram, Mark D., Weissman, Irving L.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2021
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307693/
https://ncbi.nlm.nih.gov/pubmed/34257155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2026849118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados